Glenmede Trust CO Na Uni Qure N.V. Transaction History

Glenmede Trust CO Na

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$45.06 - $67.74 $182,087 - $273,737	-4,041 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$37.13 - $74.62 $6,720 - $13,506	181 Added 4.69%	4,041 $289,000
Q3 2019 Nov 14, 2019	BUY	$39.36 - $76.8 $3,148 - $6,144	80 Added 2.12%	3,860 $151,000
Q2 2019 Aug 13, 2019	BUY	$52.76 - $82.19 $149,310 - $232,597	2,830 Added 297.89%	3,780 $295,000
Q1 2019 May 14, 2019	BUY	$27.39 - $68.41 $26,020 - $64,989	950 New	950 $56,000

141

33.7M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $237M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.